期刊文献+
共找到833篇文章
< 1 2 42 >
每页显示 20 50 100
Oxidative stress affects retinal pigment epithelial cell survival through epidermal growth factor receptor/AKT signaling pathway 被引量:10
1
作者 Xiao-Dong Chen Ming-Yang Su +3 位作者 Tao-Tao Chen Hai-Yan Hong Ai-Dong Han Wen-Sheng Li 《International Journal of Ophthalmology(English edition)》 SCIE CAS 2017年第4期507-514,共8页
AIM:To investigate the cross-talk between oxidative stress and the epidermal growth factor receptor(EGFR)/AKT signaling pathway in retinal pigment epithelial( RPE) cells.METHODS:Human RPE cell lines(ARPE-19 cel... AIM:To investigate the cross-talk between oxidative stress and the epidermal growth factor receptor(EGFR)/AKT signaling pathway in retinal pigment epithelial( RPE) cells.METHODS:Human RPE cell lines(ARPE-19 cell) were treated with different doses of epidermal growth factor(EGF) and hydrogen peroxide(H2O2).Cell viability was determined by a methyl thiazolyl tetrazolium assay.Cell proliferation was examined by a bromodeoxyuridine(Brd U) incorporation assay.EGFR/AKT signaling was detected by Western blot.EGFR localization was also detected by immunofluorescence.In addition,EGFR/AKT signaling was intervened upon by EGFR inhibitor(erlotinib),PI3 K inhibitor(A66) and AKT inhibitor(MK-2206),respectively.H2O2-induced oxidative stress was blocked by antioxidant N-acetylcysteine(NAC).RESULTS:EGF treatment increased ARPE-19 cell viabili ty and proliferation through inducing phosphorylation of EGFR and AKT.H2O2 inhibited ARPE-19 cell viability and proliferation and also suppressed EGF-stimulated increase of RPE cell viability and proliferation by affecting the EGFR/AKT signaling pathway.EGFR inhibitor erlotinib blocked EGF-induced phosphorylation of EGFR and AKT,while A66 and MK-2206 only blocked EGF-induced phosphorylation of AKT.EGF-induced phosphorylation andendocytosis of EGFR were also affected by H2O2 treatment.In addition,antioxidant NAC attenuated H2O2-induced inhibition of ARPE-19 cell viability through all eviating reduction of EGFR,and phosphorylated and total AKT proteins.CONCLUSION:Oxidative stress affects RPE cell viability and proliferation through interfering with the EGFR/AKT signaling pathway.The EGFR/AKT signaling pathway may be an important target in oxidative stress-induced RPE cell dysfunction. 展开更多
关键词 oxidative stress epidermal growth factor receptor AKT retinal pigment epithelial cell
下载PDF
Cyclooxygenase-2 and epithelial growth factor receptor up-regulation during progression of Barrett's esophagus to adenocarcinoma 被引量:14
2
作者 Yan Li John M Wo +4 位作者 Mukunda B Ray Whitney Jones Ruifeng R Su Susan Ellis Robert C G Martin 《World Journal of Gastroenterology》 SCIE CAS CSCD 2006年第6期928-934,共7页
AIM: To investigate the expression of cyclooxygenase-2 (COX-2) and epithelial growth factor receptor (EGFR) throughout the progression of Barrett's esophagus (BE). METHODS: COX-2 and EGFR protein expressions ... AIM: To investigate the expression of cyclooxygenase-2 (COX-2) and epithelial growth factor receptor (EGFR) throughout the progression of Barrett's esophagus (BE). METHODS: COX-2 and EGFR protein expressions were detected by using immunohistochemical method. A detailed cytomorphological changes were determined. Areas of COX-2 and EGFR expression were quantified by using computer Imaging System. RESULTS: The expressions of both COX-2 and EGFR increased along with the progression from BE to esophagus adenocarcinoma (EAC). A positive correlation was found between COX-2 expression and EGFR expression. CONCLUSION: COX-2 and EGFR may be cooperative in the stepwise progression from BE to EAC, thereby leading to carcinogenesis. 展开更多
关键词 Cycloxygenase -2 (COX-2) epithelial growth factor receptor egfr Barrett's esophagus CARCINOGENESIS
下载PDF
EXPRESSION AND SIGNIFICANCE OF BASIC FIBROBLAST GWOWTH FACTOR AND FIBROBLAST GROWTH FACTOR RECEPTOR-1 IN OVARIAN EPITHELIAL NEOPLASM
3
作者 高尚风 杨蓉 +1 位作者 高博 刘惠喜 《Journal of Pharmaceutical Analysis》 SCIE CAS 2003年第1期82-85,共4页
Objective To study the relevance of expression of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor 1 (FGFR 1) and carcinogenesis and progression of ovarian epithelial neoplasm. Methods Ten ... Objective To study the relevance of expression of basic fibroblast growth factor (bFGF), fibroblast growth factor receptor 1 (FGFR 1) and carcinogenesis and progression of ovarian epithelial neoplasm. Methods Ten cases of normal ovarian tissues and 75 cases of ovarian epithelial neoplasm tissues were detected by immunohistochemical methods: S P for bFGF, FGFR 1,double immunohistochemistry Lab SA for Ki 67 antigen and bFGF. Results The expression level of bFGF, FGFR 1in ovarian epithelium and ovarian epithelial neoplasm showed a step wise increase in the following order:normal <benign <borderline <malignant; The expression level and intensity of bFGF and FGFR 1 were increased with the decrease of differentiation degree and increase of clinical stage in ovarian carcinoma; There was no statistical difference between the expression of bFGF, FGFR 1 in serous cystadenocarcinoma and that of mucinous cystadenocarcinoma; The expression of bFGF was correlated with that of FGFR 1 in neoplastic tissues; There were positive expression rates of bFGF and Ki 67 antigen in ovarian epithelial neoplasm. Conclusion As an important proliferative factor, bFGF plays an important role in carcinogenisis and progression of ovarian epithelial neoplasm. 展开更多
关键词 basic fibroblast growth factor (bFGF) fibroblast growth factor receptor 1 (FGFR 1) Ki 67 antigen ovarian epithelial neoplasm
下载PDF
Relationship between molecular changes in epidermal growth factor receptor(EGFR)and anaplastic lymphoma kinase(ALK)mutations in lung adenocarcinoma
4
作者 Rina Na Wei Luan +3 位作者 Yinzai He Yanwei Gao Nier Cha Baoqin Jia 《Oncology and Translational Medicine》 CAS 2021年第4期155-159,共5页
Objective This study aimed to analyze the relationship between the mutations in epidermal growth factor receptor(EGFR)and anaplastic lymphoma kinase(ALK)and their impact on the prognosis and treatment of lung adenocar... Objective This study aimed to analyze the relationship between the mutations in epidermal growth factor receptor(EGFR)and anaplastic lymphoma kinase(ALK)and their impact on the prognosis and treatment of lung adenocarcinoma.Methods A total of 158 cases of lung adenocarcinoma reported between January 2007 and January 2014 were retrospectively analyzed.These tumors were resected using radical pneumonectomy and underwent pathology-based diagnosis at our institution(Inner Mongolia People’s Hospital,Hohhot,China).The tissue sections were evaluated using the updated World Health Organization classification of lung adenocarcinomas(2015 version),with each histological component recorded in 5%increments.The histological subtypes were classified,and any surviving cases were followed up.The reverse transcription-polymerase chain reaction(RT-PCR)and direct DNA sequencing were used to evaluate mutations in exons 18,19,20,and 21 in the EGFR gene,and the echinoderm microtubule-associated protein-like 4 gene-ALK variant(EML4-ALK)fusions were detected using sequencing.Results Our cohort included 25 patients with pre-invasive adenocarcinoma,13 patients with lepidic,66 patients with acinar,13 patients with papillary,and 25 patients with solid infiltrative adenocarcinoma with the remaining cases presenting with a variety of pathological subtypes.The prognosis of each histological subtype was different with the 5-year disease-free survival and 5-year overall survival(OS)of pre-invasion adenocarcinoma at 100%;the 5-year OS of lepidic,acinar,and papillary adenocarcinoma patients was only 84.6%,72.7%,and 76.9%,respectively.The 5-year OS of solid and mucinous adenocarcinomas were 32.0%and 36.4%,respectively.EGFR mutation was detected in 69 cases with a mutation rate of 43.7%and majority of these mutations were found in exons 19(50.6%)and 21(37.9%),with women and non-smokers shown to experience a higher mutation rate(P<0.05).However,histological subtype analysis showed that EGFR mutations were primarily found in adenocarcinomas.Most of these mutations were found in lepidic(53.8%)or acinar adenocarcinomas(50.0%),whereas these mutations were rare in both solid(28.0%)and mucinous adenocarcinoma(27.2%).The fusion mutation rate in the EML4-ALK gene was 5.69%,and was most common in young,nonsmoking patients(P<0.05).Conclusion The prognosis of patients in each lung adenocarcinoma subtype is different,and these outcomes are likely related to mutations in the EGFR and EML4-ALK genes.EGFR mutation rates are higher in lepidic and acinar adenocarcinomas,whereas EML4-ALK gene fusion mutations are more common in solid and mucinous adenocarcinoma.EGFR mutations are more common in female and non-smoking patients,whereas EML4-ALK fusions are more common in young,non-smoking patients. 展开更多
关键词 lung cancer histological subtypes prognosis the echinoderm microtubule-associated protein-like 4 gene-ALK variant(EML4-ALK) epidermal growth factor receptor(egfr)
下载PDF
非小细胞肺癌EGFR基因少见突变P733L对第1代和第3代EGFR-TKI敏感性的研究
5
作者 车娟娟 王婧 +3 位作者 甄洪超 林海珊 尚昆 俞静 《中国医院用药评价与分析》 2024年第7期774-777,782,共5页
目的:探讨表皮生长因子受体(EGFR)基因少见突变P733L对第1代和第3代EGFR酪氨酸激酶抑制剂(EGFR-TKI)的敏感性。方法:通过四唑盐比色法和平板克隆实验分析EGFR L858R和P733L肺癌细胞对第1代和第3代EGFR-TKI的敏感性;通过Transwell实验分... 目的:探讨表皮生长因子受体(EGFR)基因少见突变P733L对第1代和第3代EGFR酪氨酸激酶抑制剂(EGFR-TKI)的敏感性。方法:通过四唑盐比色法和平板克隆实验分析EGFR L858R和P733L肺癌细胞对第1代和第3代EGFR-TKI的敏感性;通过Transwell实验分析第1代和第3代EGFR-TKI对EGFR L858R和P733L肺癌细胞迁移的抑制作用;通过检测凋亡蛋白分析第1代和第3代EGFR-TKI促进EGFR L858R和P733L肺癌细胞凋亡的作用。结果:第1代和第3代EGFR-TKI对EGFR L858R和P733L细胞的增殖、克隆形成和细胞迁移都有抑制作用。与EGFR野生型肺癌细胞相比,第1代和第3代EGFR-TKI处理后,EGFR L858R和P733L细胞的EGFR激酶活性受到抑制,细胞凋亡明显增加。结论:EGFR P733L突变细胞对第1代和第3代EGFR-TKI的敏感性与EGFR L858R突变细胞的敏感性相似,本研究为EGFR基因少见突变从EGFR-TKI治疗中获益提供了实验证据。 展开更多
关键词 非小细胞肺癌 表皮生长因子受体酪氨酸激酶抑制剂 egfr少见突变 egfr P733L 药物敏感性
下载PDF
稳定过表达犬EGFR蛋白的MDCK细胞的建立及其对凋亡和细胞周期的影响
6
作者 杨迪 黄玲巍 +2 位作者 杨雅雯 乔自林 王家敏 《华北农学报》 CSCD 北大核心 2024年第4期223-230,共8页
表皮生长因子受体(EGFR)在许多实体肿瘤中过度表达,建立稳定过表达犬EGFR蛋白的MDCK细胞株,有利于为研究犬或人类肿瘤疾病提供良好的细胞模型和研究基础。首先制备目的片段以构建EGFR基因过表达载体,与慢病毒包装载体共同转染至293T细胞... 表皮生长因子受体(EGFR)在许多实体肿瘤中过度表达,建立稳定过表达犬EGFR蛋白的MDCK细胞株,有利于为研究犬或人类肿瘤疾病提供良好的细胞模型和研究基础。首先制备目的片段以构建EGFR基因过表达载体,与慢病毒包装载体共同转染至293T细胞中,48 h后提取上清液经纯化获得EGFR基因过表达慢病毒液。将其转染至MDCK细胞中,经嘌呤霉素筛选和单细胞克隆后观察感染效率,RT-qPCR和Western Blot、间接免疫荧光分别检测基因及蛋白的表达,建立EGFR蛋白过表达MDCK细胞株。使用流式细胞仪分别检测过表达及对照细胞株的细胞凋亡和细胞周期。犬EGFR基因位于18号染色体,由编码跨膜糖蛋白的30个外显子组成。经反应体系,PCR产物交换入线性化表达载体,获得了阳性转化子8个,大小为738 bp。所获EGFR基因过表达慢病毒滴度为3.5×10^(8 )TU/mL。转染MDCK细胞后在荧光显微镜下观察荧光效果显著,经检测EGFR基因及其蛋白在细胞中的表达量显著升高。间接免疫荧光试验显示,EGFR在细胞中表达明显增强。过表达细胞的早期凋亡率和晚期凋亡率显著上升,且在G2/M期发生阻滞。成功建立一株稳定的犬EGFR过表达MDCK细胞株,犬EGFR的过表达催化了细胞分裂,使DNA复制加快,同时刺激了细胞凋亡。 展开更多
关键词 犬肾细胞系 表皮生长因子受体 慢病毒载体
下载PDF
Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients 被引量:5
7
作者 Lin Li Zijin Zhang +7 位作者 Zhixin Bie Zheng Wang Ping Zhang Xin Nie Yuanming Li Hui Wang Bin Ai Gang Cheng 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2015年第3期294-300,共7页
Background: Epidermal growth factor receptor(EGFR) mutation is the key predictor of EGFR tyrosine kinase inhibitors(TKIs) efficacy in non-small cell lung cancer(NSCLC). We conducted this study to verify the fea... Background: Epidermal growth factor receptor(EGFR) mutation is the key predictor of EGFR tyrosine kinase inhibitors(TKIs) efficacy in non-small cell lung cancer(NSCLC). We conducted this study to verify the feasibility of EGFR mutation analysis in cytological specimens and investigate the responsiveness to gefitinib treatment in patients carrying EGFR mutations.Methods: A total of 210 cytological specimens were collected for EGFR mutation detection by both direct sequencing and amplification refractory mutation system(ARMS). We analyzed EGFR mutation status by both methods and evaluated the responsiveness to gefitinib treatment in patients harboring EGFR mutations by overall response rate(ORR), disease control rate(DCR) and progression free survival(PFS).Results: Of all patients, EGFR mutation rate was 28.6%(60/210) by direct sequencing and 45.2%(95/210) by ARMS(P〈0.001) respectively. Among the EGFR wild type patients tested by direct sequencing, 26.7% of them were positive by ARMS. For the 72 EGFR mutation positive patients treated with gefitinib, the ORR, DCR and median PFS were 69.4%, 90.2% and 9.3 months respectively. The patients whose EGFR mutation status was negative by direct sequencing but positive by ARMS had lower ORR(48.0% vs. 80.9%, P=0.004) and shorter median PFS(7.4 vs. 10.5 months, P=0.009) as compared with that of EGFR mutation positive patients by both detection methods. Conclusions: Our study verified the feasibility of EGFR analysis in cytological specimens in advanced NSCLC. ARMS is more sensitive than direct sequencing in EGFR mutation detection. EGFR Mutation status tested on cytological samples is applicable for predicting the response to gefitinib. Abundance of EGFR mutations might have an influence on TKIs efficacy. 展开更多
关键词 Non-small cell lung cancer (NSCLC) epidermal growth factor receptor egfr mutation cytological specimen amplification refractory mutation system (ARMS) GEFITINIB
下载PDF
柠檬醛通过EGFR信号通路抑制NCI-H1975细胞增殖
8
作者 朱威巍 聂妍 +4 位作者 翁大志 李艳丽 王宣军 黄业伟 范源洪 《食品研究与开发》 CAS 2024年第21期63-67,共5页
该文探究柠檬醛是否通过表皮生长因子受体(epidermal growth factor receptor,EGFR)信号通路诱导非小细胞肺癌(non-small cell lung cancer,NSCLC)系中NCI-H1975细胞增殖。主要采用噻唑蓝(methyl thiazolyl tetrazolium,MTT)法检测细胞... 该文探究柠檬醛是否通过表皮生长因子受体(epidermal growth factor receptor,EGFR)信号通路诱导非小细胞肺癌(non-small cell lung cancer,NSCLC)系中NCI-H1975细胞增殖。主要采用噻唑蓝(methyl thiazolyl tetrazolium,MTT)法检测细胞毒性、流式细胞术检测细胞凋亡率、分子对接探究柠檬醛与EGFR蛋白结合位点,通过蛋白质免疫印迹法(Western Blot)检测柠檬醛对EGFR及其下游细胞外调节蛋白激酶(extracellular regulated protein kinases,ERK)蛋白表达的影响。研究结果显示柠檬醛在NCI-H1975细胞系上IC50值为114.5μmol/L,且100μmol/L的柠檬醛已对NCIH1975细胞的增殖产生显著抑制作用(P<0.05),呈浓度依赖性抑制细胞增殖;流式结果显示柠檬醛可增大细胞凋亡率,促进细胞凋亡;Western Blot检测结果表明,柠檬醛在100μmol/L时对EGFR/ERK蛋白磷酸化表达有显著抑制作用(P<0.05)。综上,柠檬醛可抑制NCI-H1975细胞增殖并能促进凋亡,通过抑制EGFR信号通路传导进而发挥作用。 展开更多
关键词 柠檬醛 NCI-H1975 表皮生长因子受体 细胞增殖 细胞凋亡
下载PDF
Epidermal growth factor receptor-targeted immune magnetic liposomes capture circulating colorectal tumor cells efficiently 被引量:2
9
作者 Jing-Hua Kuai Qing Wang +4 位作者 Ai-Jun Zhang Jing-Yu Zhang Zheng-Feng Chen Kang-Kang Wu Xiao-Zhen Hu 《World Journal of Gastroenterology》 SCIE CAS 2018年第3期351-359,共9页
AIM To compare the capacity of newly developed epidermal growth factor receptor(EGFR)-targeted immune magnetic liposomes(EILs) vs epithelial cell adhesion molecule(Ep CAM) immunomagnetic beads to capture colorectal ci... AIM To compare the capacity of newly developed epidermal growth factor receptor(EGFR)-targeted immune magnetic liposomes(EILs) vs epithelial cell adhesion molecule(Ep CAM) immunomagnetic beads to capture colorectal circulating tumor cells(CTCs).METHODS EILs were prepared using a two-step method, and the magnetic and surface characteristics were confirmed. The efficiency of capturing colorectal CTCs as well as the specificity were compared between EILs and Ep CAM magnetic beads. RESULTS The obtained EILs had a lipid nanoparticle structure similar to cell membrane. Improved binding with cancer cells was seen in EILs compared with the method of coupling nano/microspheres with antibody. The binding increased as the contact time extended. Compared with Ep CAM immunomagnetic beads, EILs captured more CTCs in peripheral blood from colorectal cancer patients. The captured cells showed consistency with clinical diagnosis and pathology. Mutation analysis showed same results between captured CTCs and cancer tissues. CONCLUSION EGFR antibody-coated magnetic liposomes show high efficiency and specificity in capturing colorectal CTCs. 展开更多
关键词 EPIDERMAL growth factor receptor IMMUNE magnetic liposomes epithelial cell adhesion molecule CIRCULATING tumor cells COLORECTAL cancer
下载PDF
达可替尼联合达卡瑞利珠单抗治疗EGFR突变局部晚期NSCLC的临床疗效及安全性研究
10
作者 李秀林 李明伟 +1 位作者 陈婷婷 孙李凌 《海南医学》 CAS 2024年第18期2595-2600,共6页
目的探究达可替尼联合卡瑞利珠单抗(Cam)治疗表皮生长因子受体(EGFR)突变局部晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选取2022年1月至2023年11月濮阳市安阳地区医院收治的98例EGFR突变局部晚期NSCLC患者纳入研究,采用简单随... 目的探究达可替尼联合卡瑞利珠单抗(Cam)治疗表皮生长因子受体(EGFR)突变局部晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法选取2022年1月至2023年11月濮阳市安阳地区医院收治的98例EGFR突变局部晚期NSCLC患者纳入研究,采用简单随机化法分为对照组和研究组各49例。对照组患者给予达可替尼治疗,研究组患者给予达可替尼联合Cam治疗,21 d为一个周期,均治疗4个周期。比较两组患者的治疗效果,以及治疗前、治疗2个周期、治疗4个周期后的T淋巴细胞亚群(CD3+、CD4+、CD4+/CD8+)、血管生长因子[血小板衍生生长因子(PDGF)、血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)]、预后相关标志物[微小RNA(miRNA)-137-3p、miR-1255b-5p、miR-379-5p]、体能状态[卡氏功能状态(KPS)]和生存质量[肺癌患者生存质量评定量表(FACT-L)],并比较两组患者治疗期间的不良反应发生率。结果研究组患者的客观缓解率(ORR)为85.71%,明显高于对照组的67.35%,差异有统计学意义(P<0.05);治疗2个周期、4个周期后,研究组患者的外周血CD3+、CD4+、CD4+/CD8+水平分别为(53.63±4.58)%和(51.25±4.13)%、(35.47±3.12)%和(33.96±2.83)%、1.59±0.21和1.45±0.17,明显高于对照组的(51.45±4.23)%和(49.17±4.19)%、(33.82±3.07)%和(32.42±2.91)%、1.47±0.20和1.37±0.19,差异均有统计学意义(P<0.05);治疗2个周期、4个周期后,研究组患者的血清PDGF、VEGF、bFGF水平分别为(1.58±0.18)ng/mL和(1.13±0.09)ng/mL、(31.38±3.74)ng/L和(23.19±2.41)ng/L、(184.99±26.12)pg/mL、(135.39±19.24)pg/mL,明显低于对照组的(1.69±0.19)ng/mL和(1.21±0.13)ng/mL、(34.12±3.81)ng/L和(27.36±2.68)ng/L、(207.16±27.73)pg/mL和(172.61±23.85)pg/mL,差异均有统计学意义(P<0.05);治疗2个周期、4个周期后,研究组患者的血清miR-137-3p、miR-379-5p、miR-1255b-5p水平分别为0.68±0.15和0.71±0.19、0.53±0.12和0.65±0.15、0.40±0.09和0.49±0.11,明显高于对照组的0.55±0.14和0.63±0.18、0.46±0.11和0.57±0.13、0.35±0.08和0.44±0.10,差异均有统计学意义(P<0.05);治疗2个周期、4个周期后,研究组患者的KPS评分、FACT-L评分分别为(80.01±2.67)分和(82.64±2.79)分、(84.29±8.14)分和(102.93±9.64)分,明显高于对照组的(78.39±2.65)分和(80.92±2.73)分、(74.05±7.86)分和(85.24±8.19)分,差异均有统计学意义(P<0.05);治疗期间,研究组患者的不良反应总发生率为26.53%,略低于对照组的40.82%,但差异无统计学意义(P>0.05)。结论达可替尼联合Cam治疗EGFR突变局部晚期NSCLC患者的疗效显著,其可改善患者免疫功能,抑制肿瘤血管生长因子,有助于改善患者预后,提高患者生存质量及体能状态,且安全性良好。 展开更多
关键词 达可替尼 卡瑞利珠单抗 非小细胞肺癌 T淋巴细胞亚群 生存质量 表皮生长因子受体突变
下载PDF
循环CD4^(+)CD45RA^(+)CD62L^(+)T细胞与接受EGFR-TKI治疗的转移性非小细胞肺癌预后相关
11
作者 操辰新 唐辉 +4 位作者 耿瑞璇 郭伏平 白春梅 王颖轶 李太生 《基础医学与临床》 CAS 2024年第5期658-664,共7页
目的探索外周血循环淋巴细胞的基线水平及动态变化与接受表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗的EGFR突变阳性的转移性非小细胞肺癌患者预后之间的相关性。方法设计一个回顾性队列,包括在北京协和医院接受EGFR-TKI治疗的40... 目的探索外周血循环淋巴细胞的基线水平及动态变化与接受表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗的EGFR突变阳性的转移性非小细胞肺癌患者预后之间的相关性。方法设计一个回顾性队列,包括在北京协和医院接受EGFR-TKI治疗的40例非小细胞肺癌患者。在EGFR-TKI治疗期间,使用流式细胞仪测量术收集外周血循环淋巴细胞亚群进行动态监测,并通过电话随访每位患者的生存情况,分别比较基线以及治疗1月后外周血循环淋巴细胞亚群与无进展生存期(PFS)和总生存期(OS)的关系。结果在接受EGFR-TKI治疗的患者中,更高的基线循环CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数与更高的肿瘤治疗应答相关(P<0.001)。整个人群的PFS为27.1个月,而OS未达到。然而,基线CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数与中位PFS无相关性。此外,在EGFR-TKI治疗期间,CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数稳定或升高的患者的PFS明显长于CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数降低的患者(29.1个月对比9.4个月;P<0.001)。结论更高的基线循环CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数与更好的EGFR-TKI治疗应答相关,CD4^(+)CD45RA^(+)CD62L^(+)T细胞计数的动态变化与PFS延长有关。 展开更多
关键词 表皮生长因子受体酪氨酸激酶抑制剂(egfr-TKI) 淋巴细胞亚群 肺癌 CD4^(+)CD45RA^(+)CD62L^(+)T细胞 预后
下载PDF
EGFR突变的晚期肺腺癌患者EGFR-TKIs治疗过程中脑转移的危险因素分析
12
作者 靳俊杰 刘兆良 +2 位作者 狄艳青 曹涤非 李丽 《河北医药》 CAS 2024年第16期2423-2426,2431,共5页
目的 评估表皮生长因子受体(EGFR)突变的晚期肺腺癌患者酷氨酸激酶抑制剂(EGFR-TKIs)治疗过程中脑转移的危险因素研究,为临床诊治提供参考。方法 回顾性分析2018年1月至2020年1月收治的134例EGFR突变晚期肺腺癌患者的临床资料,均随访至2... 目的 评估表皮生长因子受体(EGFR)突变的晚期肺腺癌患者酷氨酸激酶抑制剂(EGFR-TKIs)治疗过程中脑转移的危险因素研究,为临床诊治提供参考。方法 回顾性分析2018年1月至2020年1月收治的134例EGFR突变晚期肺腺癌患者的临床资料,均随访至2023年4月30日。用Kaplan-Meier法计算脑转移的累积发病率,用多因素Cox回归分析脑转移的独立危险因素。结果 34例患者(25.4%)在EGFR-TKIs治疗过程中发生脑转移。多因素分析显示年龄≤53岁(HR:2.751,95%CI:1.326~5.707;P=0.007)、血清癌胚抗原≥23 ng/mL(HR:3.197,95%CI:1.512~6.758;P=0.002)和EGFR21外显子突变(HR:2.769,95%CI:1.355~5.659;P=0.005)是发生脑转移的独立高危因素。结论 EGFR突变的晚期肺腺癌患者EGFR-TKIs治疗过程中脑转移的危险因素较多,临床上值得注意。 展开更多
关键词 egfr突变 晚期肺腺癌 egfr-TKIs治疗 脑转移
下载PDF
第三代EGFR-TKI耐药性机制及联合用药治疗的策略 被引量:1
13
作者 周建宇 秦晓红 米立志 《中国生物化学与分子生物学报》 CAS CSCD 北大核心 2024年第2期170-179,共10页
表皮生长因子受体(epidermal growth factor receptor,EGFR)是一种受体酪氨酸激酶,参与如细胞的增殖、分裂和分化等生理过程,并在肿瘤的发生和发展中发挥重要作用。在非小细胞肺癌的靶向治疗中,靶向表皮生长因子受体的酪氨酸激酶抑制剂(... 表皮生长因子受体(epidermal growth factor receptor,EGFR)是一种受体酪氨酸激酶,参与如细胞的增殖、分裂和分化等生理过程,并在肿瘤的发生和发展中发挥重要作用。在非小细胞肺癌的靶向治疗中,靶向表皮生长因子受体的酪氨酸激酶抑制剂(tyrosine kinase inhibitor,TKI)取得了显著疗效。然而,伴随着EGFR T790M等突变的出现,患者会对第一代和第二代EGFR-TKI治疗产生耐药性。为此,开发的以奥希替尼(Osimertinib)为代表的第三代EGFR-TKI,在治疗携带EGFR T790M突变患者的耐药中取得了良好效果。但部分接受第三代EGFR-TKI治疗的患者仍会产生获得性耐药。目前,已知的耐药机制主要分为EGFR依赖型(EGFR自身激酶结构域突变)和EGFR非依赖型(异常旁路信号的激活、下游信号通路的激活、组织学表型转变)两类。本文对EGFR及第三代EGFR-TKI药物结构、主要的耐药机制和耐药后的治疗策略进行了全面综述与总结,并对未来克服EGFR-TKI耐药性的可能方向进行了分析。 展开更多
关键词 表皮生长因子受体 酪氨酸激酶抑制剂 奥希替尼 耐药机制 联合用药
下载PDF
阿帕替尼联合埃克替尼治疗EGFR基因21号外显子L858R突变型NSCLC的临床观察
14
作者 罗娜 马慧丽 杨启 《实用癌症杂志》 2024年第4期594-597,共4页
目的探究对表皮生长因子受体(EGFR)基因21号外显子L858R突变型非小细胞肺癌(NSCLC)采用阿帕替尼联合埃克替尼治疗的临床效果。方法将EGFR基因21号外显子L858R突变型NSCLC患者101例按随机数表法分为观察组(n=51)与对照组(n=50)。观察组... 目的探究对表皮生长因子受体(EGFR)基因21号外显子L858R突变型非小细胞肺癌(NSCLC)采用阿帕替尼联合埃克替尼治疗的临床效果。方法将EGFR基因21号外显子L858R突变型NSCLC患者101例按随机数表法分为观察组(n=51)与对照组(n=50)。观察组采用阿帕替尼联合埃克替尼治疗,对照组仅采用埃克替尼治疗,治疗时间为56 d,2个周期。比较2组近期疗效、不良反应,并采用K-M生存分析曲线图分析2组远期疗效。结果观察组与对照组的客观缓解率(ORR)(74.51%vs 74.00%)与疾病控制率(DCR)(92.16%vs 94.00%)差异均无统计学意义(P>0.05);治疗期间2组未出现2级以上不良反应,观察组高血压和蛋白尿发生率分别为52.94%、50.98%,分别高于对照组的16.00%、10.00%,差异有统计学意义(P<0.05)。观察组生存率显著高于对照组(69.3%vs 43.1%),差异有统计学意义(P<0.05)。结论EGFR基因21号外显子L858R突变型NSCLC采用阿帕替尼联合埃克替尼治疗,可延长患者的无进展生存时间,不良反应的发生可接受。 展开更多
关键词 非小细胞肺癌 阿帕替尼 埃克替尼 表皮生长因子受体 21号外显子L858R突变型
下载PDF
乳腺癌组织中EGFR、GATA-3、E-Cad的表达及其与预后的关系
15
作者 颜佳 段鑫 宋芳霞 《实用癌症杂志》 2024年第10期1608-1610,共3页
目的探讨表皮生长因子受体(EGFR)、GATA结合蛋白3(GATA-3)、上皮性钙黏附蛋白(E-cad)在乳腺癌组织内的表达及其与患者预后的关系。方法选取89例乳腺癌患者,术中采集所有患者的癌组织与癌旁正常组织(距离病灶边缘≥3 cm),将其分别纳入观... 目的探讨表皮生长因子受体(EGFR)、GATA结合蛋白3(GATA-3)、上皮性钙黏附蛋白(E-cad)在乳腺癌组织内的表达及其与患者预后的关系。方法选取89例乳腺癌患者,术中采集所有患者的癌组织与癌旁正常组织(距离病灶边缘≥3 cm),将其分别纳入观察组、对照组,统计对比2组EGFR、GATA-3、E-Cad阳性表达差异。另随访1年,统计对比不同EGFR、GATA-3、E-Cad表达患者的生存率。结果观察组EGFR、GATA-3阳性表达率高于对照组,E-Cad阳性表达率低于对照组,差异有统计学意义(P<0.05);EGFR、GATA-3、E-Cad表达与患者肿瘤的分化程度、淋巴结转移、临床分期有关,差异有统计学意义(P<0.05)。EGFR、GATA-3阳性表达患者的生存率低于阴性表达患者,E-Cad阴性表达患者的生存率低于阳性表达患者,差异有统计学意义(P<0.05)。结论EGFR、GATA-3在乳腺癌组织内呈高表达,E-Cad呈低表达,三者表达与乳腺癌患者的生存率具有紧密联系。 展开更多
关键词 乳腺癌 表皮生长因子受体 GATA结合蛋白3(GATA-3) 上皮性钙黏附蛋白 预后
下载PDF
Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia - induced cell death 被引量:4
16
作者 Steinbach JP Klumpp A +1 位作者 Wolburg H Weller M 《中国神经肿瘤杂志》 2004年第1期22-22,共1页
Epidermal growth factor receptor(EGFR)signaling has become an importanttarget for drug development becauseEGFR signaling enhances tumor cell proliferation,migration,and invasion and inhibits apoptosis.However,theresul... Epidermal growth factor receptor(EGFR)signaling has become an importanttarget for drug development becauseEGFR signaling enhances tumor cell proliferation,migration,and invasion and inhibits apoptosis.However,theresults of clinical trials using EGFR inhibitors in patients with solid tumors have been disappointing.Here,wereport a protective effect of the EGFR inhibitors AG1478 and PD153035 against cell death induced by acute hy-poxia,which contrasts with their proapoptotic effects under normoxia.Under hypoxic conditions,both agents re- 展开更多
关键词 egfr Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia induced cell death
下载PDF
Mogroside IIE,an in vivo metabolite of sweet agent,alleviates acute lung injury via Pla2g2a-EGFR inhibition
17
作者 Weichao Lü Guoqing Ren +2 位作者 Kuniyoshi Shimizu Renshi Li Chaofeng Zhang 《Food Science and Human Wellness》 SCIE CSCD 2024年第1期299-312,共14页
In the face of increasingly serious environmental pollution,the health of human lung tissues is also facing serious threats.Mogroside IIE(M2E)is the main metabolite of sweetening agents mogrosides from the anti-tussiv... In the face of increasingly serious environmental pollution,the health of human lung tissues is also facing serious threats.Mogroside IIE(M2E)is the main metabolite of sweetening agents mogrosides from the anti-tussive Chinese herbal Siraitia grosvenori.The study elucidated the anti-inflammatory action and molecular mechanism of M2E against acute lung injury(ALI).A lipopolysaccharide(LPS)-induced ALI model was established in mice and MH-S cells were employed to explore the protective mechanism of M2E through the western blotting,co-immunoprecipitation,and quantitative real time-PCR analysis.The results indicated that M2E alleviated LPS-induced lung injury through restraining the activation of secreted phospholipase A2 type IIA(Pla2g2a)-epidermal growth factor receptor(EGFR).The interaction of Pla2g2a and EGFR was identified by co-immunoprecipitation.In addition,M2E protected ALI induced with LPS against inflammatory and damage which were significantly dependent upon the downregulation of AKT and m TOR via the inhibition of Pla2g2a-EGFR.Pla2g2a may represent a potential target for M2E in the improvement of LPS-induced lung injury,which may represent a promising strategy to treat ALI. 展开更多
关键词 Mogroside IIE Acute lung injury Secreted phospholipase A2 type IIA(Pla2g2a) Epidermal growth factor receptor(egfr)
下载PDF
LncRNA AFAP1-AS1 exhibits oncogenic characteristics and promotes gemcitabine-resistance of cervical cancer cells through miR-7-5p/EGFR axis
18
作者 CHAOQUN WANG TING ZHANG CHAOHE ZHANG 《Oncology Research》 SCIE 2024年第12期1867-1879,共13页
Background:Drug resistance is the main factor contributing to cancer recurrence and poor prognosis.Exploration of drug resistance-related mechanisms and effective therapeutic targets are the aim of molecular targeted ... Background:Drug resistance is the main factor contributing to cancer recurrence and poor prognosis.Exploration of drug resistance-related mechanisms and effective therapeutic targets are the aim of molecular targeted therapy.In our study,the role of long non-coding RNA(lncRNA)AFAP1-AS1 in gemcitabine resistance and related mechanisms were explored in cervical cancer cells.Methods:Gemcitabine-resistant cervical cancer cell lines HT-3-Gem and SW756-Gem were constructed using the gemcitabine concentration gradient method.The overall survival rates and recurrence-free survival rates were evaluated by Kaplan-Meier analysis.The interaction was verified through a Dual-luciferase reporter gene assay and a Biotinylated RNA pull-down assay.Cell proliferation ability was assessed through methyl-thiazolyl-tetrazolium(MTT),soft agar,and colony formation experiments.Cell cycle and apoptosis were detected byflow cytometry.Results:Up-regulation of AFAP1-AS1 in cervical cancer predicted a poor prognosis.Besides,patients in the gemcitabine-resistance group had higher levels of AFAP1-AS1 than the gemcitabine-sensitive group.AFAP1-AS1 promoted tumor growth and induced gemcitabine tolerance of cervical cancer cells.In addition,AFAP1-AS1 mediated epidermal growth factor receptor(EGFR)expression by serving as a molecular sponge for microRNA-7a-5p(miR-7-5p).This present study also proved that the knockdown of EGFR or overexpression of miR-7a-5p abolished the accelerative role of AFAP1-AS1 overexpression in cancer progression and gemcitabine tolerance.Conclusions:In general,the AFAP1-AS1/miR-7-5p/EGFR axis was tightly related to the progression and gemcitabine tolerance of cervical cancer,providing potential targets for the management of cervical cancer. 展开更多
关键词 Long non-coding RNA(lncRNA)AFAP1-AS1 miR-7-5p Epidermal growth factor receptor(egfr) Gemcitabine-resistance Cervical cancer
下载PDF
抗OX40/EGFR双特异性抗体的制备和活性鉴定
19
作者 晋瑞娜 边海波 +2 位作者 张晓敏 杨帆 王晚萍 《首都医科大学学报》 CAS 北大核心 2024年第2期296-301,共6页
目的构建同时靶向表皮生长因子受体(epidermal growth factor receptor,EGFR)和OX40的双特异性抗体,并在体外初步验证其对T细胞的特异性激活作用。方法构建抗OX40/EGFR双特异性抗体的真核表达载体,转染293F细胞进行表达和纯化。构建外... 目的构建同时靶向表皮生长因子受体(epidermal growth factor receptor,EGFR)和OX40的双特异性抗体,并在体外初步验证其对T细胞的特异性激活作用。方法构建抗OX40/EGFR双特异性抗体的真核表达载体,转染293F细胞进行表达和纯化。构建外源表达OX40和EGFR的HEK293T细胞,利用流式细胞术分析双抗与靶蛋白表达细胞的结合活性。并利用Jurkat-OX40-NF-κB-GFP报告细胞,验证双特异性抗体对报告细胞的激活活性。通过酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)检测外周血单个核细胞(peripheral blood mononuclear cell,PBMC)的白细胞介素-2(interleukin-2,IL-2)和γ-干扰素(interferon-γ,IFN-γ)分泌,进一步验证抗OX40/EGFR双抗对原代T细胞的激活。结果成功构建并且纯化了抗OX40/EGFR双特异性抗体,并且验证了该双抗可以特异性地结合表达EGFR和OX40的HEK293T细胞。在表达EGFR的A549肺癌细胞介导的交联作用下,该双特异性抗体较OX40单抗更强地激活OX40-NF-κB报告细胞,并且促进PBMC分泌IL-2和IFN-γ细胞因子。结论抗OX40/EGFR双特异性抗体构建成功,可同时识别OX40和EGFR受体并激活肿瘤特异性T细胞。 展开更多
关键词 OX40 表皮生长因子受体 双特异性抗体 癌症 T细胞激活
下载PDF
EGFR Mutation and FHIT Methylation: Inverse Relationship in Patients with Lung Adenocarcinoma and Tuberculosis
20
作者 Mireguli Abudureheman Xiuyou Yan Baidurula Ainitu 《Proceedings of Anticancer Research》 2024年第2期65-72,共8页
Objective:To investigate the genetic correlations between epithelial growth factor receptor(EGFR)mutation and FHIT methylation in patients diagnosed with lung adenocarcinoma(AC)and pulmonary tuberculosis(TB).Methods:T... Objective:To investigate the genetic correlations between epithelial growth factor receptor(EGFR)mutation and FHIT methylation in patients diagnosed with lung adenocarcinoma(AC)and pulmonary tuberculosis(TB).Methods:The presence of EGFR mutations and the methylation status of the FHIT gene in patients presenting with AC and TB were analyzed.The correlation between TB status and the observed genetic and epigenetic variations was also examined.Results:Among the 90 patients included in the study,38 exhibited EGFR mutations(14 among those with TB and 24 among those without TB),while 29 exhibited FHIT myelination(19 among those with TB and 10 among those without TB).Furthermore,the protein expression levels of EGFR and FHIT were significantly higher in patients diagnosed solely with AC compared to those presenting with both AC and TB.A robust inverse correlation was identified between TB status and the frequency of EGFR mutation(P<0.001).Moreover,significant associations were observed between TB status and FHIT methylation(P<0.01).Conclusion:The findings suggest a correlation between TB and the prevalence of EGFR mutation and FHIT methylation in the pathogenesis of AC. 展开更多
关键词 Lung cancer Adenocarcinoma(AC) Tuberculosis(TB) epithelial growth factor receptor(egfr) Fragile histidine triad(FHIT)
下载PDF
上一页 1 2 42 下一页 到第
使用帮助 返回顶部